A Phase II Evaluation of Brivanib (BMS582664, IND105029), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Trial Profile

A Phase II Evaluation of Brivanib (BMS582664, IND105029), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Brivanib alaninate (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Sep 2013 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 18 Jul 2012 Planned End Date changed from 1 Apr 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top